Trial Profile
Pilot Study of Everolimus in the Treatment of Neoplasms in Patients With Peutz-Jeghers Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Pancreatic cancer; Peutz-Jeghers syndrome
- Focus Therapeutic Use
- Acronyms EVAM; EVAMP
- Sponsors Novartis
- 01 Apr 2018 This study was aborted due to lack of accrual in 2016, according to results published in the Oncologist.
- 10 Feb 2012 Official title amended as reported by ClinicalTrials.gov.
- 23 Nov 2010 Additional lead trial investigator (Heinz-Josef Klumpen) identified as reported by ClinicalTrials.gov.